The Introduction of Biosimilars - Uncharted Waters?

Published: 9 Apr 2014

Report from a Stakeholder Event. Revised June 2016

The emergence onto the UK market of Biosimilars is an exciting but equally concerning prospect. How will they be regulated and monitored? Will they be subject to the same rigorous assessment through the NICE Health Technology Appraisals as the original biologic therapies? How will information be shared with patients? What are the potential benefits to patients, the NHS and the economy? What are the potential issues, important to patients, that may arise?

It was with these issues in mind that a meeting for stakeholders was discussed with the Association of British Pharmaceutical Industry’s Biosimilars Taskforce by the National Rheumatoid Arthritis Society (NRAS). NRAS convened a steering group of patient organisations representing Immune Mediated Inflammatory Diseases to shape the content and focus of this meeting.  The Stakeholder event took place in April 2014 and here is the report from that meeting and the NRAS position paper on Biosimilar Medicines.

This learning module developed by the Biosimilars Patient Event steering committee was  funded by an unrestricted educational grant from the Association of the British Pharmaceutical Industry (ABPI) Biosimilars Group. Members of the group include the BioIndustry Association (BIA), AbbVie, Amgen, Bristol Myers Squibb, MSD, Pfizer, Novartis and Sanofi. The Biosimilars Patient event was developed independently and the Biosimilars Patient Event steering committee retained full control of the content